Phase II study of neoadjuvant chemotherapy with SOX + bevacizumab in patients with locally advanced rectal cancer
- Conditions
- Rectal cancer
- Registration Number
- JPRN-UMIN000015320
- Lead Sponsor
- Asahikawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
1) Any distant metastases 2) Neurological disorder by cerebrovascular disorder within a year before enrollment 3) Symptomatic heart disease or heart disease requiring treatment. Cardiac infarction within a year before enrollment 4) Pleural, peritoneal and pericardial effusion 5) Prior systematic chemotherapy, pelvic irradiation and/or surgery for malignant tumor 6) Active double cancer. Asynchronous double cancer with disease-free duration of 5 years or less. (Including colorectal cancer) 7) Interstitial pneumonia or pulmonary fibrosis 8) Poorly controlled infection 9) Grade 2 or worse peripheral neuropathy 10) Bowel obstruction (Patients with diverting stoma are allowed for enrollment) 11) Poorly controlled diarrhea 12) Confirmed or possible pregnancy, lactation, willingness to become pregnant (for women), or willingness to have a child (for men) 13) Contraindication of bevacizumab 14) Physician concludes that the patient's participation in this trial is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method R0 resection rate
- Secondary Outcome Measures
Name Time Method